TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01710943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavioral Treatment
Description: Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week.
Study: NCT00599391

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation for 30 to 40 minutes per session.
Study: NCT01165320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Study: NCT00453115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
Study: NCT02019446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Treatment YAG laser
Description: YAG Laser / FOX Laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment (control group) terbinafine hydrochloride tablets
Description: Terbinafine hydrochloride tablets tablets
Study: NCT02210689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate vaginal cream 2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate vaginal cream 2%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vehicle used as placebo
Study: NCT02365467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Thoracic Stent Graft System
Study: NCT02829281

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Joint injection of Saline
Study: NCT01553149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03666897

Intervention type: OTHER
Group type: OTHER
Intervention: DTI Images and Plasma Biomarkers
Description: Additional Images added from standard of care MRI, Bio-markers identified
Study: NCT01689870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40
Description: Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40
Description: Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40
Description: Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40
Description: Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
Study: NCT00508625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 951 (rhApo2L/TRAIL)
Description: AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 951 (rhApo2L/TRAIL)
Description: AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 951 (rhApo2L/TRAIL)
Description: AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Standard platinum based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard platinum based chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Standard platinum based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard platinum based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard platinum based chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Standard taxane chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard taxane chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Standard taxane chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard taxane chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard taxane chemotherapy
Study: NCT04319120

Intervention type: OTHER
Intervention: questionnaires online
Description: Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed. A dedicated telephone line and e-mail address will be used as a support if necessary (for questionnaires, emails or sending photos). The referring nurse and the clinical research assistant of the service will be in charge of centralizing the data collected.
Study: NCT01269060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Surgery
Description: Single Incision Laparoscopic Sigmoidectomy
Study: NCT02539277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinyebaidu granule
Description: It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fufangshuanghua granule
Description: It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jinyebaidu granule placebo
Description: It is Jinyebaidu granule placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fufangshuanghua granule placebo
Description: It is Fufangshuanghua granule placebo.
Study: NCT01060930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-NMMA and Nor-epinephrine
Description: Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
Study: NCT01389921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalography
Description: Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
Study: NCT01211106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
Study: NCT02906657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation
Description: The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
Study: NCT02945059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective reversible portal vein embolization
Description: Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
Study: NCT00084435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV, Day 1, q 21 days for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 15 mg/m2 IV, Day 1, 1 7 days for 6 doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 200 cGy/day, Days 1-5, q week for 6 weeks
Study: NCT00357994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa carbidopa intestinal gel (LCIG)
Description: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PBO) oral capsules

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: J-tube
Description: jejunal tube
Study: NCT01946594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01911156

Intervention type: DRUG
Group type: OTHER
Intervention: Continue NA treatment
Description: Prescribed NA during the 72 week study period

Intervention type: DRUG
Group type: OTHER
Intervention: Discontinue NA Treatment
Description: Discontinue NA Treatment
Study: NCT03658915

Intervention type: DEVICE
Intervention: Smartphone application (Goniometer Pro )
Description: Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.

Intervention type: DEVICE
Intervention: Smartphone application (Goniometer Pro )
Description: Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
Study: NCT00692913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)
Description: FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Supplement 500 mg
Description: Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day).

Intervention type: OTHER
Group type: OTHER
Intervention: Referred-Care Model
Description: Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
Study: NCT00477282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin
Description: Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
Study: NCT03929575

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of calcium
Description: Ingestion of 250 mg of calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhodiola
Description: Ingestion of 250 mg of Rhodiola
Study: NCT03442777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allevyn® brand silicone adhesive multilayer foam dressings
Description: Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith\&Nephew (Allevyn® brand).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® brand silicone adhesive multilayer foam dressings
Description: Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
Study: NCT05304624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: these lasers are routinely used in dental practice

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: these lasers are routinely used in dental practice
Study: NCT02027259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Description: The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
Study: NCT02821936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parametric Imaging
Description: 2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
Study: NCT04149132

Intervention type: DEVICE
Intervention: pulse photoplethysmography (PPG)
Description: PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
Study: NCT01940575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SkinPlus-Hyal®
Description: The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane®
Description: The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
Study: NCT03929575

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhodiola and Cordyceps
Description: Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
Study: NCT00721552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: 28 days administration of 100 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: 28 days administration of 100 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg
Description: 14 days administration of 30 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg
Description: 14 days administration of 30 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin-placebo
Description: 28 days administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin-placebo
Description: 28 days administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone-placebo
Description: 14 days administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone-placebo
Description: 14 days administration once daily
Study: NCT00633386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
Study: NCT04149132

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of nitric oxide (NO) and malondialdehyde (MDA)
Description: On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
Study: NCT00633386

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT02103556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral oil
Description: 4 ml daily (adjusted as needed), for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 4 ml daily (adjusted as needed), for 4 weeks